HDBuzz

@hdbuzzfeed

Huntington’s disease research news. In plain language. Written by scientists. hdbuzz.net Editors - @sjh508 @rjharding

48 Folgt256 Follower1.407 Posts

Bluesky

Ist das dein Profil?Übernimm es — dann gehört dir hdbuzzfeed.dirty.social.Profil übernehmen

HDBuzz@hdbuzzfeed· 2h

Which HTT should we target? Human trials may give us an answer before laboratory experiments!

HDBuzz@hdbuzzfeed· 8h

When scientists test a new method, they ask questions about whether it’s working as expected, and how well it might work in animal models (and eventually in people). #HD2026

HDBuzz@hdbuzzfeed· 9h

Day 1 of #HD2026 - From what human brains can teach us about HD, to HTT1a, somatic CAG expansion and the normal biology of HTT, today’s talks spanned the spectrum from fundamental biology to potential treatments. Catch up on everything we learned right here. en.hdbuzz.net/hd-2026-milt...

HDBuzz@hdbuzzfeed· 9h

Jim Gusella describes two interacting wheels that drive HD, expanded huntingtin and somatic instability, and a third wheel of additional genetic modifiers that we don’t yet understand. #HD2026

HDBuzz@hdbuzzfeed· 10h

Ideally, everything scientists learn, from the level of DNA all the way up to populations of humans who are monitored over time, can be combined to contribute to our understanding of HD. #HD2026

HDBuzz@hdbuzzfeed· 10h

Vanessa Wheeler reminds us that the study of somatic instability has a long history in HD research.

HDBuzz@hdbuzzfeed· 2d

Anne's slide covering current and potential HD therapies in development - lots of shots on goal! #HD2026

HDBuzz@hdbuzzfeed· 6d

Prilenia Therapeutics has donated data from two of its Huntington’s Disease (HD) clinical trials to CHDI Foundation, creating a valuable resource that researchers can use to better understand placebo effects, disease progression and future trial design. en.hdbuzz.net/prilenia-sha...

Text reads: Although data sharing has become increasingly common across biomedical research, it has not always been routine, so this is an important step forward for the field.

Text reads: Researchers will use the data to better understand placebo effects, disease progression and how to improve the design and interpretation of future clinical trials.

Text reads: In a disease where every participant and every dataset is precious, this an important investment in the future of HD research.

HDBuzz@hdbuzzfeed· 9d

Roche's decision to stop development of two huntingtin-lowering programmes is disappointing, but the story doesn't end there. Years of research have answered some key questions, raised many new ones, and will inform the next generation of HD trials. Read about it here: en.hdbuzz.net/looking-back...

A road with arrows, one pointing forward and one back. Title words on screen: "Looking Back & Moving Forward - Four weeks after Roche announced two Huntington's disease programs were closing, questions remain..."

HDBuzz@hdbuzzfeed· 13d

July was a hard month for Huntington’s disease research, with Roche ending two HD programs. But the month also brought promising new tools to visualize and track huntingtin, and important studies on eating and self-awareness in HD. Read the full recap: en.hdbuzz.net/july-2026-th...

Sketch of someone reading a newspaper that's on fire. On the firey side is "HARD NEWS" and the fire's out smoking side is "CONTINUING PROGRESS".

HDBuzz@hdbuzzfeed· 16d

Published ANX005 trial results show the drug is safe, works as designed and may help people with Huntington’s disease - so what’s the holdup? en.hdbuzz.net/putting-it-i...

Trial drug to rein in runaway pruning is safe, so what’s next? HD can affect how well the immune system works within brain cells. Immune support cells called microglia “prune” unnecessary or damaged brain cell connections. But in people with HD, microglia can become overactive and “prune” (eliminate) useful connections. ANX005 (tanruprubart) aims to correct that immune system imbalance. The study showed the drug works as designed, has potential for benefit, and is safe. So what now?

HDBuzz@hdbuzzfeed· 29d

Skyhawk Therapeutics have received the regulatory approval needed to broaden its FALCON-HD trial to include the United States, Canada, and the UK. The expanded trial will enroll up to 400 more people with Stage 2 and early Stage 3 HD across more than 40 sites worldwide.

HDBuzz@hdbuzzfeed· Jul 9

Roche announced it is stopping development of two of its huntingtin-lowering ASO drugs, tominersen and RG6496. This marks a disappointing end to an important chapter in HD clinical research. en.hdbuzz.net/roche-ends-t...

HDBuzz@hdbuzzfeed· Mar 18

Novartis has confirmed that the first clinical sites for INVEST-HD, the Phase 3 trial of votoplam, are now open. The study plans to recruit around 770 participants across 30+ countries, marking a major step forward in advancing potential treatments for Huntington’s disease.

HDBuzz@hdbuzzfeed· Feb 26

To check that these 3D cell clumps actually mimic the human brain, Alice and her team visualize all of the different cell types in globe-shaped maps to see exactly where they all are in the structure and how well they are all working together. #HDTC2026

HDBuzz@hdbuzzfeed· Feb 26

HDBuzz@hdbuzzfeed· Feb 25

Gene’s lab uses cool tools that allow them to understand what proteins bind the HTT RNA message, in very specific locations within the cell. He thinks that the expanded huntingtin RNA is acting to reorganize its environment - pulling in extra proteins and making a mess! #HDTC2026

HDBuzz@hdbuzzfeed· Feb 25

The final talk before we break for coffee is from Bogdan Bintu from the University of California San Diego. Bogdan starts by telling the audience how much he loves building microscopes! #HDTC2026

HDBuzz@hdbuzzfeed· Feb 25

In this model, Steve’s team define different phases of HD which they think best explain the data and observations they have made from studying HD brains. They think expansions start slow at first, and rapidly increase as more CAG repeats are added. #HDTC2026

HDBuzz@hdbuzzfeed· Feb 25

Another key focus for his team is on understanding why making the expanded HTT protein is toxic in some parts of the brain, but not so much for other tissues or organs. #HDTC2026

HDBuzz@hdbuzzfeed· Feb 25

Latus is using computer modeling to build predictive models about how much their therapeutic could improve HD progression. #HDTC2026

HDBuzz@hdbuzzfeed· Feb 24

Elena shows us super cool images of the brain-like cell systems her team uses - awesome!

HDBuzz@hdbuzzfeed· Nov 11

To close out 2025, we're celebrating those who move Huntington's disease research forward, from scientists to families, closing this year with the gratitude we feel for the HD community.